Advanced Small Animal Ultrasound Imaging - Vevo F2

先进的小动物超声成像 - Vevo F2

• 批准号: 10632878
• 负责人: Timothy McKinsey
• 金额: $ 45.47万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-05 至 2024-06-04
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10632878
• 关键词: Animals; Applications Grants; Area; Basic Science; Biomedical Research; Blood Vessels; Blood flow; Cardiac; Cardiology; Cardiorenal syndrome; Cardiovascular Models; Cardiovascular system; Cells; Clinical; Collaborations; Colorado; Core Facility; Data; Disease; Fee-for-Service Plans; Funding; Goals; Heart; Human; Impairment; Inferior; Injections; Kidney; Lung; Measurement; Medical; Medical center; Medicine; Metabolic; Metabolic Diseases; Modeling; Monitor; Mus; Neoplasm Metastasis; Operating System; Pancreas; Pathogenesis; Pediatric Hospitals; Portal vein structure; Pre-Clinical Model; Rattus; Request for Proposals; Research; Research Personnel; Resolution; Rodent Model; Role; Science; Services; Structure; System; Technology; Testing; Therapeutic; Therapeutic Agents; Translating; Translations; Ultrasonography; United States National Institutes of Health; Universities; animal facility; biomarker discovery; contrast imaging; equipment acquisition; human disease; imaging system; innovation; instrument; metropolitan; novel therapeutics; pathogen; pre-clinical; right ventricular remodeling; tool; tumor; ultrasound

PROJECT SUMMARY/ABSTRACT This proposal requests funds for the acquisition of a state-of-the-art Vevo F2 high-resolution ultrasound imaging system (FujiFilm-VisualSonics). This system would be integrated into and managed by the Pre-Clinical Cardiovascular (PCC) Core facility within the Division of Cardiology/Department of Medicine at the University of Colorado Denver Anschutz Medical Campus (AMC). Due to the highly advanced technology of the Vevo F2, this system would significantly expand the current capabilities of the PCC Core and would enhance on-going, system-wide collaborations at the University of Colorado. The long-term objective of this proposal is to provide advanced ultrasound capabilities that lead to a more detailed understanding of pathophysiological mechanisms and highlight potential therapeutic strategies that could be translated into innovative treatments for human diseases. Our goal is to do the best science possible and be guided by the data. Having a Vevo F2 instrument in our PCC Core would undoubtedly help us achieve this goal. A major focus of the PCC Core to facilitate studies employing mouse and rat models of cardiovascular, pulmonary, renal, metabolic and onocologic diseases. Our ultimate goal is to translate findings made in these pre-clinical models into novel therapeutics for the treatment of devastating diseases in humans. We collaborate closely with research groups across the campus, and the entire Denver metropolitan area, to understand the roles of heart:kidney and heart:lung cross-talk in the pathogenesis of cardiorenal disease and pulmonary vascular/right ventricular remodeling. Additionally, we have collaborations focused on vascular stiffening, impaired blood flow, metabolic disease, tumor metastasis, biomarker discovery and contrast imaging in rodent models (see Figure). All of these efforts would benefit from the acquisition of a Vevo F2 instrument, which would enable state-of-the-art, non-invasive, longitudinal measurements of cardiac structure and function, renal, cardiac and pancreatic blood flow, and tumor formation in mouse and rat models. In addition, this high-definition ultrasound system would provide an invaluable tool for monitoring localized delivery of cells and therapeutic agents via intra-cardiac or portal vein injection. The Vevo F2, which has many features in common with clinical instruments, would have a tremendous impact on NIH-funded research at the University of Colorado Anschutz Medical Campus, and has the potential to facilitate translation of basic science discoveries into innovative treatments for human disease. In addition to the aforementioned collaborations, through fee-for-service arrangements, the PCC Core serves a diverse group of investigators, not only on the AMC, which has two separate animal facilities, but also in the Colorado Children's Hospital, the Rocky Mountain Regional VA Medical Center, and University of Colorado Boulder. We are also deeply committed to assisting early stage investigators obtain preliminary data to support their first NIH grant applications. For all of these studies we employ two Vevo 2100 instruments, which are located in a pathogen-free animal facility in Research Center 2 (RC2). The upgrade to the Vevo F2 is crucially needed to meet the increasing demands, and technical needs, of a multitude of projects, which have tested the limits of the Vevo 2100 instruments that we purchased in 2014. Not only is the technology of this instrument inferior to that of the Vevo F2, but the Vevo 2100 will no longer be serviced by FujiFilm-VisualSonics starting in 2023. Furthermore, the Vevo 2100 uses a Windows XP operating system, which is not compatible with the IT requirements of the University of Colorado. It is essential that we obtain a Vevo F2 to maintain and promote cutting edge biomedical research at the University of Colorado.

项目概要/摘要 该提案请求资金用于购买最先进的 Vevo F2 高分辨率超声成像 系统（FujiFilm-VisualSonics）。该系统将集成到临床前实验室并由其管理 心血管 (PCC) 大学心脏病学部/医学系内的核心设施 科罗拉多州丹佛安舒茨医学园区 (AMC)。由于 Vevo F2 的高度先进技术， 该系统将显着扩展 PCC 核心的当前功能，并增强持续的、 科罗拉多大学的全系统合作。该提案的长期目标是提供 先进的超声功能可以更详细地了解病理生理机制 并强调可以转化为人类创新疗法的潜在治疗策略 疾病。我们的目标是尽可能地进行最好的科学研究并以数据为指导。拥有 Vevo F2 仪器 我们的 PCC Core 无疑会帮助我们实现这一目标。 PCC 核心的一个主要重点是促进使用小鼠和大鼠心血管模型的研究， 肺、肾、代谢和肿瘤疾病。我们的最终目标是转化这些研究成果 将临床前模型转化为治疗人类毁灭性疾病的新疗法。我们合作 与整个校园和整个丹佛大都市区的研究小组密切合作，以了解 心：肾和心：肺相互作用在心肾疾病和肺疾病发病机制中的作用 血管/右心室重塑。此外，我们的合作重点是血管硬化， 啮齿动物血流受损、代谢疾病、肿瘤转移、生物标志物发现和对比成像 模型（见图）。所有这些努力都将受益于购买 Vevo F2 仪器，这将 能够对心脏结构和功能、肾脏、心脏进行最先进的、非侵入性的纵向测量 小鼠和大鼠模型中的胰腺血流量以及肿瘤形成。此外，这款高清 超声系统将为监测细胞的局部输送和治疗提供宝贵的工具。 通过心脏内或门静脉注射药剂。这 Vevo F2 与 Vevo F2 有许多共同点 临床仪器，将会产生巨大的影响 科罗拉多大学 NIH 资助的研究 安舒茨医学园区，有潜力 促进基础科学发现转化为 人类疾病的创新疗法。 除了上述合作之外， 通过按服务收费的安排，PCC 核心 为不同的研究人员群体提供服务，不仅在 AMC 有两个独立的动物设施，但是 也在科罗拉多州洛基儿童医院 退伍军人山区地区医疗中心和大学 科罗拉多州博尔德。我们也深深地致力于 协助早期研究人员获得 支持他们的第一笔 NIH 拨款的初步数据 应用程序。对于所有这些研究，我们采用了两个 Vevo 2100 仪器位于 研究中心 2 的无病原体动物设施 （RC2）。 Vevo F2的升级至关重要 需要满足日益增长的需求，以及 众多项目的技术需求 测试了我们的 Vevo 2100 仪器的极限 2014年购买的。这不仅是技术 仪器不如 Vevo F2，但 Vevo 从 2023 年开始，FujiFilm-VisualSonics 将不再为 2100 提供服务。此外，Vevo 2100 使用 Windows XP操作系统，与科罗拉多大学的IT要求不兼容。 我们必须获得 Vevo F2 以维持和促进尖端生物医学研究 科罗拉多大学。